Pharmacokinetics and retinal toxicity of intravitreal liposome-encapsulated 5-fluorouridine

Ophthalmologica

Volumn 211, Issue 6, 1997, Pages 344-350

  García Arumí, José ^a   Pascual, Roser ^b   Fonseca, José ^c   Reig Isart, Francesca ^c   Casaroli, Ricardo ^b   Mateo, Carlos ^a   Corcóstegui, Borja ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b Universidad Central   (Spain)

^c Consejo Superior Investigaciones Científicas ^*  (Slovenia)

Author keywords

5 Fluorouridine; Antimetabolites; Fluoropyrimidines; Liposomes; Proliferative vitreoretinopathy; Retinal toxicity

Indexed keywords

ANTIMETABOLITE; CHOLESTEROL; COLLAGEN; CYCLOPENTOLATE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURIDINE; LIPOSOME; PHOSPHATIDYLCHOLINE;

A WAVE; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; B WAVE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; ELECTRORETINOGRAPHY; ENCAPSULATION; EYE TOXICITY; INTRAVITREAL DRUG ADMINISTRATION; NONHUMAN; RABBIT; VITREORETINOPATHY; VITREOUS BODY;

EID: 1842335695     PISSN: 00303755     EISSN: 14230267     Source Type: Journal    
DOI: 10.1159/000310826     Document Type: Article

References (42)

1. Glaser BM, Cardin A, Biscoe B: Proliferative vitreorctinopathy: The mechanism of development of vitreoretinal traction, Ophthalmology 1987:94:327.
2. Machemcr R: Pathogenesis and classification of massive periretinal proliferation, Br J Ophthalmol 1978:62:737.
3. Rachal WF, Burton TC: Changing concepts of failure after retinal detachment surgery, Arch Ophthalmol 1979:97:480-483.
4. Laqua H, Machemer R: Glial cell proliferation in retinal detachment (massive periretinal proliferation), Am.1 Ophthalmol 1975:80:602.
5. Wilkes SR, Mansour AM, Green WR: Proliferative vitreorctinopathy: llistopathology of rct-rorctinal membranes, Retina 1987;7:94.
6. Campochiaro PA, Glaser BM: Mechanisms involved in retinal pigment epithelial cell ehemo-taxis, Arch Ophthalmol 1986:104:277.
7. Garcia-Arumi J, Corcostegui C, Tallada N: Sub-retinal membranes in proliferative vitreoretino-pathy: An immunohistochemical study, Retina 1992:12:S55-S59.
8. Ryan S.I: The pathophysiology of proliferative vitreorctinopathy in its management, Am J Ophthalmol 1985:100:188.
9. Michels RG, Wilkinson CP, Rice TA (eds): Retinal Detachment, St Louis, Mosby, 1990, pp 680-750.
10. Rowen SL, Glaser BM: Retinal pigment epithelial cells release a chcmoattractant for astrocytes, Arch Ophthalmol 1985:103:704.
11. Tano Y, Chandler D, Machemer R: Inhibition of intraocular proliferation with intravitreal injection of triamcinolone acctonide, Am J Ophthalmol 1980:90:810-816.
12. Wiedemann P, Lemmen K, Schmicdl R, Hei-mann K: Intraocular daunorubiein for the treatment and prophylaxis of traumatic proliferative vitreorctinopathy, Am J Ophthalmol 1987:104: 10-14.
13. Davis AA, Whidby DE, Privette T, et al: Selective inhibition of growing pigment epithelial cells by a receptor-directed immunotoxin, Invest Ophthalmol Vis Sci 1990;31:2514-2519.
14. Hartzer MK, Blumcnkranz MS, Hajek AS, et al: Selection of therapeutic agents for intraocular proliferative disease: Effects of fluoropyrimi-dines on cell-mediated contraction of human fibroblast, Exp Eye Res 1989:48:321-328.
15. Heath TD, Lopez NG, Lewis GP, Stem WH: Antiproliferative and antieontractilc effects of liposome-encapsulated fluoroorotate, Invest Ophthalmol Vis Sei 1987:28:1365-1372.
16. Blumenkranz M, Ophir A, Clafin A, Hajek A: Fluorouracil for the treatment of massive panrc-tinal proliferation, Am J Ophthalmol 1982:94: 458.
17. Blumenkranz M, Hernandez E, Ophir A, Norton E: 5-Fluorouracil:New applications in complicated retinal detachment for an established antimetabolite, Ophthalmology 1984:91:122.
18. Blumenkranz M, Clafiin A, Hajek A: Selection of therapeutic agents for intraocular proliferative disease, Arch Ophthalmol 1984; 102:598.
19. Blumenkranz M, Hajek A, Hernandez E, Hartzer M: Fluorouridine: A second generation ocular antimetabolite (ARVO abstracts), Invest Ophthalmol Vis Sei 1985;26(suppl):285.
20. Huang D, Blumcnkranz M, Hernandez E, Hartzer M: Uptake and clearance of 5-fluorou-ridinc following subconjunctival and intravitreal injection, Retina 1988:8:205.
21. l4C-fluorouracil in rabbits, Arch Ophthalmol 1979:97:23-75.
22. Kulnig W, Binder S, Riss B, Skorpik C: Inhibition of experimental intraocular proliferation with intravitreous 5-fluorouracil: A transmission electron microscopic study in rabbits, Ophthalmologies 1984; 188:248.
23. Binder S, Riss B, Skorpik C, Kulnig W: Inhibition of experimental intraocular proliferation with intravitreal 5-fluorouracil, Graefcs Arch Clin Exp Ophthalmol 1983:221:126.
24. Gariano R, Assil K, Svendsen R Munguia D, Lynn G, Heckcnlively J, Weinreb R, Freeman W: Retinal toxicity of intravitreal injection of FUMP using mult ¡vesicular liposomes (ARVO abstracts), Invest Ophthalmol Vis Sei 1990: 31 (suppl):306.
25. Blumenkranz MS, Hartzer MK, Hajek AS: Selection of therapeutic agents for intraocular proliferative disease, II, Differing antiproliferative activity of the fluoropyrimidines, Arch Ophthalmol 1987:105:396-399.
26. Jarus G, Blumenkranz M, Flcrnandez E, Sossi N: Clearance of intravitreal fluorouracil: Normal and aphakic vitrcctomized eyes: Ophthalmology 1985;92:91-96.
27. Assil KK, Weinreb RN: Sustained release of the antimetabolite cytarabine in the eye, Arch Ophthalmol 1987:105:400-403.
28. Barza M, Baum J, Szoka F: Pharmacokinetics of subconjunctival liposome-encapsulated gen-tamicin in normal rabbit eyes, Invest Ophthalmol Vis Sei 1984:25:486.
29. Shaeffer HE, Krohn DL: Liposomes in topical drug delivery, Invest Ophthalmol Vis Sei 1982: 22:220.
30. Lee WHL, Urrea PT, Smith RE, Schanzlin D.I: Ocular drug bioavailability from topically applied liposomes, Sur\ Ophthalmol 1985:29: 335.
31. Tremblay C, Barza M, Szoka F, Lahav M, Baum I: Reduced toxicity of liposome-associated amphotericin B injected intrax itrcally in rabbits, Invest Ophthalmol Vis Sei 1985:26:711.
32. Barza M, Baum I, Tremblay C, Szoka F, DAmico J: Ocular toxicity of intravitreally injected liposomal amphotericin B in rhesus monkeys, Am J Ophthalmol 1985:100:259.
33. Assil KK, Lane J, Weinreb RN: Sustained release of the antimctabolitc 5-fluorouridinc-5'-monophosphate by multivesicular liposomes, Ophthalmic Surg 1988:19:408-413.
34. Assil KK, Hartzer M, Weinreb RN, Nehorayan M, Ward T, Blumenkranz M: Liposome suppression of proliferative vitreoretinopathy, Invest Ophthalmol Vis Sei 1991:32:2891-2897.
35. Lee VHL., Urrea PT, Smith RE, Schanzlin DJ: Ocular drug bioavailability for topically applied liposomes, Surv Ophthalmol 1985:29:335-338.
36. Simmons ST, Sherwood MB, Nichols DA, Penne RB, Sery T, Spaeth GL: Pharmacokinetics of a 5-fluorouracil liposomal delivery system, BrJ Ophthalmol 1988:72:688-691.
37. Stem WH, Heath TD, Lewis GP, Guerin CJ, Erickson PA, Lopez NG, Hong K: Clearance and localization of intravitreal liposomes in the aphakic vitrectomized eye, Invest Ophthalmol VisSci 1987;28:907-911.
38. Van Borssum WM, Van Galen M, Morselt II, Sternberg B, Scherphof GL: In vitro stability and cytostatic activity of liposomal formulations of 5-fluoro-5-desoxyuridinc and its diacy-clated derivatives, Biochim Biophys Acta 1993; 1148:161-172.
39. Kirby C, Grcgoriadis G: Dehydration-rehydra-tion vesicles: A simple method for high yield drug entrapment in liposomes, Biotechnology 1984;2:979-982.
40. Kirby C, Clarke J, Grcgoriadis G: Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro, Bio-chem J 1980:186:591.
41. McClare CWF: An accurate and convenient organic phosphorous assay, Anal Biochem 1971; 39:527-530.
42. Barza M, Stuart M, Szoka F: Effect of size and lipid composition on the pharmacokinetics of intravitreal liposomes, Invest Ophthalmol Vis Sci 1987:28:893-900.